Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda is expanding its targeted protein degradation playbook with a $1.2 billion collaboration with Shanghai-based Degron Therapeutics to discover molecular…
Takeda and Degron Therapeutics launched a collaboration worth up to $1.2 billion in upfront, milestones, and equity to discover molecular glue degraders…
Degron Therapeutics closed a $40 million Series A extension ($95M total raised) to support clinical development of its molecular glue degraders. Lead program…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Degron Therapeutics announced collaboration and exclusive license agreement with Takeda to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation. Upfront payment plus milestones totaling up to $1.2B, tiered royalties, and an equity investment from Takeda. Degron retains full ownership of its pipeline. Review update (June 2026): the Takeda collaboration remains ongoing with no public milestone disclosure or termination. Degron has independently advanced its platform — lead asset DEG6498, a first-in-class oral HuR molecular glue degrader, entered a Phase 1 first-in-human study in advanced solid tumors (NCT07244835) with first patient dosed in November 2025, and the company closed a $40M Series A extension on May 14, 2026 (>$95M total raised), with two immunology programs targeted for development-candidate selection in 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Degron Therapeutics Ltd. (this deal) | 2024 | $1.2B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · Takeda Pharmaceutical Company Ltd. deals · Immunology deals